Nikkei average contribution ranking (advance closing) ~ The Nikkei Average rebounded, and TOEREC boosted by about 61 yen with 1 brand

The number of gains and falls of the Nikkei Average constituent stocks as of closing 26 days ago was 121 stocks with a price increase and 101 stocks with a price drop of 3 stocks unchanged. The Nikkei Average rebounded. The front-end transaction was closed at 37780.35 yen (estimated volume of 740 million shares), which was 151.87 yen higher (+0.40%) compared to the previous day. The US stock market declined on the 25th. The Dow average depreciated by 375.12 dollars (-0.98%) at 38085.80 dollars, and the NASDAQ depreciated 100.99 points (-0.64%) at 15611.

Fisco JapanApr 25 23:21 ET

Brands that moved the day before part 2 Sakura Gome, Smart Value, Chugai Pharmaceutical, etc.

<コード>Stock name closing price on the 25th ⇒ compared to the previous day Pana HD ＜6752＞ 1325 -68 earnings forecasts were revised downward centered on transient factors. CyberAgent ＜4751＞ 976.5 -58.5 The first half of the year's positive financial results were also exhausted, and the feeling prevailed. GURUNAVI ＜2440＞ broke through the 302-1325 line and had an advantage in closeout sales. Chugai Pharmaceutical＜4519＞ 4860-291 saw a drastic decrease in sales for the first quarter. Hino Motors ＜7205＞ 462.6 -29.325 financial results

Fisco JapanApr 25 18:32 ET

Earnings Call Summary | CHUGAI PHARMACEUTICAL CO(CHGCF.US) Q1 2024 Earnings Conference

The following is a summary of the Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript:Financial Performance:Chugai Pharmaceutical's Q1 2024 revenue reported a decrease of 24.1% ye

moomoo AIApr 25 04:53 ET · Conference Call

Meta Water, Canon, Avionics, etc.

＜4519＞ Chugai Pharmaceutical 4860-291 continued to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. sluggish

Fisco JapanApr 25 02:57 ET

Movements to avoid risk due to concerns about the performance of Japanese and American companies

The Nikkei Average fell sharply. The transaction closed at 37628.48 yen (estimated turnover of 1.59 billion shares), which depreciated by 831.60 yen. Profit-taking sales took precedence from the reaction that had risen by over 900 yen the day before. Also, the fact that US Meta Platforms, which showed a sluggish earnings forecast, was plummeting overtime worsened investor sentiment, and performance unease of domestic high-tech companies was also alarmed, and the Nikkei Average remained soft throughout the day. The fact that US stock index futures continue to be soft also strengthens the buy-off attitude

Fisco JapanApr 25 02:54 ET

Chugai Pharmaceutical --- drastic decline, with a drastic decline in sales in the first quarter

Chugai Pharmaceutical ＜4519＞ continues to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. Negative low headlines

Fisco JapanApr 25 01:26 ET